• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).广义风险调整成本效益评估(GRACE)的扩展和实施指南。
Eur J Health Econ. 2022 Apr;23(3):433-451. doi: 10.1007/s10198-021-01367-0. Epub 2021 Sep 8.
2
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach.健康技术评估的收益递减与健康:广义风险调整成本效益(GRACE)方法。
Value Health. 2021 Feb;24(2):244-249. doi: 10.1016/j.jval.2020.10.003. Epub 2021 Jan 12.
3
Health technology assessment with risk aversion in health.健康风险厌恶的卫生技术评估。
J Health Econ. 2020 Jul;72:102346. doi: 10.1016/j.jhealeco.2020.102346. Epub 2020 Jun 6.
4
Methods to Adjust Willingness-to-Pay Measures for Severity of Illness.调整支付意愿衡量标准以适应疾病严重程度的方法。
Value Health. 2023 Jul;26(7):1003-1010. doi: 10.1016/j.jval.2023.02.001. Epub 2023 Feb 14.
5
Willingness to pay for quality and length of life gains in end of life patients of different ages.不同年龄临终患者对生命质量和长度增益的支付意愿。
Soc Sci Med. 2021 Jun;279:113987. doi: 10.1016/j.socscimed.2021.113987. Epub 2021 May 4.
6
Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.患者疾病严重程度和年龄与健康相关生活质量收益相关的支付意愿。
Value Health. 2021 Aug;24(8):1182-1192. doi: 10.1016/j.jval.2021.01.012. Epub 2021 Apr 29.
7
Willingness to pay for a QALY: theoretical and methodological issues.支付意愿以获取一个质量调整生命年:理论与方法学问题。
Pharmacoeconomics. 2005;23(5):423-32. doi: 10.2165/00019053-200523050-00002.
8
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.英国国家卫生与临床优化研究所成本效益阈值的估计方法。
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.
9
Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea-hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure.阻塞性睡眠呼吸暂停低通气综合征口腔下颌前移装置随机对照试验(TOMADO)的临床疗效和成本效益结果以及口腔装置与持续气道正压通气的长期经济分析。
Health Technol Assess. 2014 Oct;18(67):1-296. doi: 10.3310/hta18670.
10
Willingness to pay vs lottery equivalent to value the impact of alcohol misuse on quality of life.支付意愿与彩票等价物评估酒精滥用对生活质量的影响。
Expert Rev Pharmacoecon Outcomes Res. 2022 Jul;22(5):835-844. doi: 10.1080/14737167.2022.2004124. Epub 2021 Nov 25.

引用本文的文献

1
Measuring the Budget Impact of Nondiscriminatory Cost-Effectiveness.衡量非歧视性成本效益的预算影响。
JAMA Health Forum. 2025 Sep 5;6(9):e253076. doi: 10.1001/jamahealthforum.2025.3076.
2
Platform Technology for Extended Reality Biofeedback Training Under Operant Conditioning for Functional Limb Weakness: Protocol for the Coproduction of an at-Home Solution (React2Home).用于功能性肢体无力的操作性条件反射下扩展现实生物反馈训练的平台技术:家庭解决方案(React2Home)的联合生产方案
JMIR Res Protoc. 2025 Aug 22;14:e70620. doi: 10.2196/70620.
3
Health Risk and the Value of Life.健康风险与生命价值。
J Public Econ. 2025 May;245. doi: 10.1016/j.jpubeco.2025.105346. Epub 2025 Apr 3.
4
The Paradigm Shift From Patient to Health Consumer: 20 Years of Value Assessment in Health.从患者到健康消费者的范式转变:健康领域20年的价值评估
J Med Internet Res. 2025 Jan 10;27:e60443. doi: 10.2196/60443.
5
An Access-Focused Patient-Centric Value Assessment Framework for Medication Formulary Decision-Making in Immune-Mediated Inflammatory Diseases.一种以免疫介导炎症性疾病药物处方集决策为重点的以患者为中心的价值评估框架。
Adv Ther. 2025 Feb;42(2):568-578. doi: 10.1007/s12325-024-03076-5. Epub 2024 Dec 20.
6
Generalized cost-effectiveness analysis: charting a path forward for measuring the societal value of medical technologies.广义成本效益分析:为衡量医疗技术的社会价值绘制前进道路。
J Comp Eff Res. 2025 Jan;14(1):e240213. doi: 10.57264/cer-2024-0213. Epub 2024 Nov 26.
7
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices.重视药品和其他卫生技术的社会影响:当前最佳实践用户指南。
Forum Health Econ Policy. 2024 Nov 8;27(1):29-116. doi: 10.1515/fhep-2024-0014. eCollection 2024 Jun 1.
8
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.估算在美国使用多奈单抗对早期有症状阿尔茨海默病进行限期治疗的经济合理价格。
Neurol Ther. 2024 Dec;13(6):1641-1659. doi: 10.1007/s40120-024-00649-y. Epub 2024 Sep 18.
9
A principled approach to non-discrimination in cost-effectiveness.基于原则的成本效益非歧视方法。
Eur J Health Econ. 2024 Nov;25(8):1393-1416. doi: 10.1007/s10198-023-01659-7. Epub 2024 Feb 27.
10
Incorporating Real Option Value in Valuing Innovation: A Way Forward.将实物期权价值纳入创新估值:一种前进的方式。
Pharmacoeconomics. 2024 Jul;42(Suppl 2):199-210. doi: 10.1007/s40273-024-01352-4. Epub 2024 Feb 4.

本文引用的文献

1
Estimating optimal willingness to pay thresholds for cost-effectiveness analysis: A generalized method.估算成本效益分析的最优意愿支付阈值:一种广义方法。
Health Econ. 2021 Jul;30(7):1697-1702. doi: 10.1002/hec.4268. Epub 2021 Apr 21.
2
Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.样本限制与每质量调整生命年恒定支付意愿的 elicitation。
Health Econ. 2021 May;30(5):923-931. doi: 10.1002/hec.4236. Epub 2021 Feb 10.
3
Health Technology Assessment With Diminishing Returns to Health: The Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Approach.健康技术评估的收益递减与健康:广义风险调整成本效益(GRACE)方法。
Value Health. 2021 Feb;24(2):244-249. doi: 10.1016/j.jval.2020.10.003. Epub 2021 Jan 12.
4
Health technology assessment with risk aversion in health.健康风险厌恶的卫生技术评估。
J Health Econ. 2020 Jul;72:102346. doi: 10.1016/j.jhealeco.2020.102346. Epub 2020 Jun 6.
5
Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis.健康总寿命:成本效益分析的一个新健康目标函数。
Value Health. 2020 Jan;23(1):96-103. doi: 10.1016/j.jval.2019.10.014. Epub 2019 Dec 24.
6
A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis.一种确定成本效益分析中最佳意愿支付的新方法。
Value Health. 2019 Jul;22(7):785-791. doi: 10.1016/j.jval.2019.03.003. Epub 2019 May 17.
7
An elicitation of utility for quality of life under prospect theory.前景理论下生活质量效用的引出
J Health Econ. 2016 Jul;48:121-34. doi: 10.1016/j.jhealeco.2016.04.002. Epub 2016 May 2.
8
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force.构建离散选择实验的实验设计:ISPOR 联合分析实验设计良好实践工作组报告。
Value Health. 2013 Jan-Feb;16(1):3-13. doi: 10.1016/j.jval.2012.08.2223.
9
Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.英国成年人对 NICE、癌症药物基金以及基于价值的药物优先排序定价标准的看法:一项对 4118 名成年人的横断面调查。
Health Econ. 2013 Aug;22(8):948-64. doi: 10.1002/hec.2872. Epub 2012 Sep 7.
10
Exploring the social value of health-care interventions: a stated preference discrete choice experiment.探索医疗保健干预措施的社会价值:一项陈述偏好离散选择实验。
Health Econ. 2009 Aug;18(8):951-76. doi: 10.1002/hec.1414.

广义风险调整成本效益评估(GRACE)的扩展和实施指南。

A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).

机构信息

School of Pharmacy, Sol Price School of Public Policy, The Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.

The National Bureau of Economic Research (NBER), Cambridge, MA, USA.

出版信息

Eur J Health Econ. 2022 Apr;23(3):433-451. doi: 10.1007/s10198-021-01367-0. Epub 2021 Sep 8.

DOI:10.1007/s10198-021-01367-0
PMID:34495445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8964662/
Abstract

The generalized risk-adjusted cost-effectiveness (GRACE) model generalizes conventional cost-effectiveness analysis (CEA) by introducing diminishing returns to Health-Related Quality of Life (QoL). This changes CEA practice in three ways: (1) Willingness to pay (WTP) increases exponentially with untreated illness severity or pre-existing permanent disability, and WTP ends up lower for mild diseases but higher for severe diseases compared with conventional CEA; (2) Average treatment effectiveness should be adjusted for uncertainty in outcomes; and (3) The marginal rate of substitution between life expectancy and QoL varies with health state. Implementing GRACE requires new parameters describing risk preferences over QoL, the marginal rate of substitution between life expectancy (LE) and QoL, and the variance and skewness of treatment outcomes distributions. In this paper, we provide: (1) a generalized WTP threshold incorporating the possibility of permanent disability; (2) a simpler method to estimate the tradeoff rate between QoL and LE, eliminating the need to carry out treatment-by-treatment estimates; (3) a more-general method to adjust WTP for illness severity that permits non-constant relative risk-aversion in QoL; (4) a new approach to estimating risk-preferences over QoL, leveraging established empirical methods from "happiness" economics; and (5) a step-by-step guide for practitioners wishing to implement multi-period GRACE analyses.

摘要

广义风险调整成本效益(GRACE)模型通过引入健康相关生活质量(QoL)的收益递减来推广传统的成本效益分析(CEA)。这在以下三个方面改变了 CEA 实践:(1)未治疗疾病严重程度或预先存在的永久性残疾的意愿支付(WTP)呈指数增长,与传统 CEA 相比,轻度疾病的 WTP 较低,但严重疾病的 WTP 较高;(2)应根据结果的不确定性调整平均治疗效果;(3)预期寿命和 QoL 之间的边际替代率随健康状况而变化。实施 GRACE 需要新的参数来描述对 QoL 的风险偏好、预期寿命(LE)和 QoL 之间的边际替代率,以及治疗结果分布的方差和偏度。在本文中,我们提供了:(1)包含永久性残疾可能性的广义 WTP 阈值;(2)一种更简单的方法来估计 QoL 和 LE 之间的权衡率,消除了逐个治疗进行估计的需要;(3)一种更通用的方法来调整 WTP 以适应疾病严重程度,允许 QoL 中的非恒定相对风险厌恶;(4)一种新的方法来估计 QoL 的风险偏好,利用“幸福”经济学中已建立的实证方法;(5)希望实施多期 GRACE 分析的从业者的分步指南。